2012 Annual Meeting | Clinical Approach to Muscle Disease

Date Saturday 04/28/12

Time 09:00 AM - 01:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type AM Half-Day Course

Director(s) Anthony A. Amato, MD, FAAN

Topic(s)

Learning Objectives Participants should be familiar with the differential diagnoses and how to evaluate and treat patients with different myopathies.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist

Teaching Styles Case-based, Audience Participation

Program Evaluations

Event Timeline
09:00 AM - 09:50 AM		Approach to Patients with Myopathy: A Pattern Recognition Approach Carlayne E. Jackson, MD, FAAN
09:50 AM - 10:40 AM		Toxic Myopathies Andrew Mammen, MD, PhD
10:40 AM - 10:50 AM		Questions and Answers
10:50 AM - 11:05 AM		Break
11:05 AM - 11:55 AM		Muscle Channelopathies Richard J. Barohn, MD, FAAN
11:55 AM - 12:45 PM		Metabolic Myopathies Anthony A. Amato, MD, FAAN
12:45 PM - 01:00 PM		Questions and Answers

Faculty Disclosures
Anthony A. Amato, MD, FAAN	Dr. Amato has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Johnson & Johnson. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abscuro. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Caballeta. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Amato has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Viridian Therapeutics. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medpace. Dr. Amato has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for legal firms. The institution of Dr. Amato has received research support from NIH. Dr. Amato has received publishing royalties from a publication relating to health care.
Richard J. Barohn, MD, FAAN	Dr. Barohn has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for NuFactor. The institution of Dr. Barohn has received research support from FDA OPD R01. Dr. Barohn has received intellectual property interests from a discovery or technology relating to health care.
Carlayne E. Jackson, MD, FAAN	Dr. Jackson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mitsubishi Tanabe Pharma America. Dr. Jackson has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for AAN. The institution of Dr. Jackson has received research support from NIH. The institution of Dr. Jackson has received research support from Massachussetts General Hospital.
Andrew Mammen, MD, PhD	Dr. Mammen has received research support from National Institutes of Health. The institution of an immediate family member of Dr. Mammen has received research support from National Institutes of Health. Dr. Mammen has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��